Achieve Life Sciences Inc (ACHV) Stake Increased by Worth Venture Partners LLC

Worth Venture Partners LLC lifted its stake in shares of Achieve Life Sciences Inc (NASDAQ:ACHV) by 180.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 89,632 shares of the biopharmaceutical company’s stock after acquiring an additional 57,632 shares during the quarter. Worth Venture Partners LLC’s holdings in Achieve Life Sciences were worth $108,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc boosted its stake in shares of Achieve Life Sciences by 169.3% during the 3rd quarter. Vanguard Group Inc now owns 35,468 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 22,299 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Achieve Life Sciences during the 3rd quarter worth about $116,000. Sio Capital Management LLC bought a new stake in shares of Achieve Life Sciences during the 3rd quarter worth about $523,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Achieve Life Sciences by 206.3% during the 3rd quarter. Renaissance Technologies LLC now owns 167,061 shares of the biopharmaceutical company’s stock worth $526,000 after acquiring an additional 112,525 shares in the last quarter. Institutional investors own 21.86% of the company’s stock.

Separately, Zacks Investment Research downgraded Achieve Life Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th.

Shares of ACHV traded down $0.05 during trading hours on Friday, hitting $2.93. 301 shares of the company were exchanged, compared to its average volume of 4,850,975. The company has a market cap of $21.31 million, a PE ratio of -0.82 and a beta of 2.75. Achieve Life Sciences Inc has a 52 week low of $1.04 and a 52 week high of $14.60.

Achieve Life Sciences (NASDAQ:ACHV) last announced its earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.18). On average, research analysts predict that Achieve Life Sciences Inc will post -1.47 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.com-unik.info/2019/03/22/achieve-life-sciences-inc-achv-stake-increased-by-worth-venture-partners-llc.html.

Achieve Life Sciences Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Recommended Story: What is the float in trading stocks?

Want to see what other hedge funds are holding ACHV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achieve Life Sciences Inc (NASDAQ:ACHV).

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit